JP2018509404A - デスアセトキシツブリシンｈおよびその類似体 - Google Patents

デスアセトキシツブリシンｈおよびその類似体 Download PDF

Info

Publication number
JP2018509404A
JP2018509404A JP2017545239A JP2017545239A JP2018509404A JP 2018509404 A JP2018509404 A JP 2018509404A JP 2017545239 A JP2017545239 A JP 2017545239A JP 2017545239 A JP2017545239 A JP 2017545239A JP 2018509404 A JP2018509404 A JP 2018509404A
Authority
JP
Japan
Prior art keywords
substituted
cycloalkyl
alkanediyl
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509404A5 (enExample
Inventor
キリアコス シー． ニコラウ
キリアコス シー． ニコラウ
ディノシオス ヴォウロウミス
ディノシオス ヴォウロウミス
ジュン イン
ジュン イン
ローハン エランデ
ローハン エランデ
デバシス マンダル
デバシス マンダル
フィリップ クラン
フィリップ クラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rice University
Original Assignee
Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rice University filed Critical Rice University
Publication of JP2018509404A publication Critical patent/JP2018509404A/ja
Publication of JP2018509404A5 publication Critical patent/JP2018509404A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017545239A 2015-02-25 2016-02-25 デスアセトキシツブリシンｈおよびその類似体 Pending JP2018509404A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562120613P 2015-02-25 2015-02-25
US62/120,613 2015-02-25
US201662275667P 2016-01-06 2016-01-06
US62/275,667 2016-01-06
PCT/US2016/019604 WO2016138288A1 (en) 2015-02-25 2016-02-25 Desacetoxytubulysin h and analogs thereof

Publications (2)

Publication Number Publication Date
JP2018509404A true JP2018509404A (ja) 2018-04-05
JP2018509404A5 JP2018509404A5 (enExample) 2019-04-04

Family

ID=56789084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545239A Pending JP2018509404A (ja) 2015-02-25 2016-02-25 デスアセトキシツブリシンｈおよびその類似体

Country Status (22)

Country Link
US (1) US10808007B2 (enExample)
EP (1) EP3261443B1 (enExample)
JP (1) JP2018509404A (enExample)
KR (1) KR20170137725A (enExample)
CN (1) CN107529754A (enExample)
AU (1) AU2016222575A1 (enExample)
BR (1) BR112017018305A2 (enExample)
CA (1) CA2977589A1 (enExample)
CL (1) CL2017002170A1 (enExample)
CO (1) CO2017008600A2 (enExample)
CR (1) CR20170438A (enExample)
DO (1) DOP2017000202A (enExample)
EA (1) EA201791896A1 (enExample)
EC (1) ECSP17057131A (enExample)
GT (1) GT201700190A (enExample)
HK (1) HK1248069A1 (enExample)
IL (1) IL254089A0 (enExample)
MX (1) MX2017011024A (enExample)
PE (1) PE20180355A1 (enExample)
PH (1) PH12017501539A1 (enExample)
SG (1) SG11201706820RA (enExample)
WO (1) WO2016138288A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
WO2019008506A1 (en) * 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
MA50124A (fr) * 2017-09-08 2020-07-15 Seattle Genetics Inc Procédé de préparation de tubulysines et d'intermédiaires de celles-ci
US11274124B2 (en) 2017-11-29 2022-03-15 William Marsh Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
WO2021004516A1 (en) * 2019-07-11 2021-01-14 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing 2-indolinospirone compound and intermediate thereof
US11694341B2 (en) 2019-12-23 2023-07-04 Texas Instmments Incorporated Cascaded architecture for disparity and motion prediction with block matching and convolutional neural network (CNN)
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
CN112645833A (zh) * 2021-01-29 2021-04-13 上海吉奉生物科技有限公司 一种(s)-2,6-二氨基-5-氧己酸的合成方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239713A1 (en) * 2002-07-09 2005-10-27 R&D-Biopharmaceuticals Am Novel tubulysin analogues
WO2008106080A2 (en) * 2007-02-27 2008-09-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof
WO2008138561A1 (en) * 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
JP2011500835A (ja) * 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
JP2011037846A (ja) * 2009-07-22 2011-02-24 Kemotech Srl 医薬組成物
JP2012503621A (ja) * 2008-09-25 2012-02-09 ユニベルシタート デス サーランデス 生物活性プレチューブリシンおよびその使用
JP2013501055A (ja) * 2009-08-03 2013-01-10 メダレックス インコーポレーティッド 抗増殖性化合物、その抱合体、そのための方法ならびにその使用
JP2013535220A (ja) * 2010-08-06 2013-09-12 エンドサイト，インコーポレイテッド ツブリシンを調製するためのプロセス
JP2013536171A (ja) * 2010-07-19 2013-09-19 ライプニッツ−インスティチュート フュア プフランツェンビオケミ チューブリシン類似体
WO2015157594A1 (en) * 2014-04-11 2015-10-15 Medimmune Llc Tubulysin derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
EP2322537A1 (en) 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Tubulin inhibitors
WO2011069116A1 (en) * 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239713A1 (en) * 2002-07-09 2005-10-27 R&D-Biopharmaceuticals Am Novel tubulysin analogues
WO2008106080A2 (en) * 2007-02-27 2008-09-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof
WO2008138561A1 (en) * 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
JP2011500835A (ja) * 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
JP2012503621A (ja) * 2008-09-25 2012-02-09 ユニベルシタート デス サーランデス 生物活性プレチューブリシンおよびその使用
JP2011037846A (ja) * 2009-07-22 2011-02-24 Kemotech Srl 医薬組成物
JP2013501055A (ja) * 2009-08-03 2013-01-10 メダレックス インコーポレーティッド 抗増殖性化合物、その抱合体、そのための方法ならびにその使用
JP2013536171A (ja) * 2010-07-19 2013-09-19 ライプニッツ−インスティチュート フュア プフランツェンビオケミ チューブリシン類似体
JP2013535220A (ja) * 2010-08-06 2013-09-12 エンドサイト，インコーポレイテッド ツブリシンを調製するためのプロセス
WO2015157594A1 (en) * 2014-04-11 2015-10-15 Medimmune Llc Tubulysin derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOEMLING, ALEXANDER; BECK, BARBARA: "Total synthesis of tubulysin U and V", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 45, JPN6019048761, 2006, pages 7235 - 7239, ISSN: 0004330425 *
PATTERSON, ANDREW W.; PELTIER, HILLARY M.: "Expedient Synthesis of N-Methyl Tubulysin Analogues with High Cytotoxicity", JOURNAL OF ORGANIC CHEMISTRY, vol. 73(12), JPN6019048759, 2008, US, pages 4362 - 4369, ISSN: 0004330423 *
WANG, ZHIYONG; MCPHERSON, PETER A.: "Structure-activity and high-content imaging analyses of novel tubulysins", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 70(2), JPN6019048760, 2007, pages 75 - 86, ISSN: 0004330424 *

Also Published As

Publication number Publication date
WO2016138288A1 (en) 2016-09-01
GT201700190A (es) 2018-11-26
CL2017002170A1 (es) 2018-06-08
CR20170438A (es) 2018-01-30
EP3261443A1 (en) 2018-01-03
IL254089A0 (en) 2017-10-31
EP3261443A4 (en) 2018-09-26
US20180127463A1 (en) 2018-05-10
AU2016222575A1 (en) 2017-09-07
US10808007B2 (en) 2020-10-20
CA2977589A1 (en) 2016-09-01
PE20180355A1 (es) 2018-02-21
BR112017018305A2 (pt) 2018-04-17
CO2017008600A2 (es) 2018-02-09
PH12017501539A1 (en) 2018-02-05
CN107529754A (zh) 2018-01-02
SG11201706820RA (en) 2017-09-28
DOP2017000202A (es) 2017-09-29
KR20170137725A (ko) 2017-12-13
EP3261443B1 (en) 2021-04-28
MX2017011024A (es) 2017-10-20
EA201791896A1 (ru) 2018-02-28
ECSP17057131A (es) 2019-03-29
HK1248069A1 (zh) 2018-10-12

Similar Documents

Publication Publication Date Title
EP3261443B1 (en) Desacetoxytubulysin h and analogs thereof
US10889590B2 (en) Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
CN108271371B (zh) 用于抑制精氨酸酶活性的组合物和方法
CN111032672B (zh) 作为抗癌剂的环二核苷酸
US11584754B2 (en) Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof
JP2025501287A (ja) Ｍｅｎｉｎ阻害剤及びその用途
US10874646B2 (en) Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
US11274124B2 (en) Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
JP2018525346A (ja) シシジマイシンａ及びその類似体の全合成
US20210230178A1 (en) Trioxacarcin analogs and dimers as potent anticancer agents
Nicolaou et al. Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
US20210238187A1 (en) Aziridine containing epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200824